1. In patients with pathological complete response to neoadjuvant systemic therapy, there was no tumour recurrence at 2 years 2. ...
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared to trastuzumab emtansine 2. Adverse events were more ...
1. Patients with refractory HER2-mutant non-small cell lung cancer (NSCLC) show clinical response to trastuzumab deruxtecan. 2. Safety profiles were ...
1. Almost 30% of patients had an objective response rate, with roughly three-quarters experiencing a reduction in tumour size. 2. ...
1. Among HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab (Herceptin), 3 year survival without invasive disease was ...
1. The addition of ramucirumab, a VEGF-2 receptor blocker, to docetaxel did not significantly increase progression free or overall survival in ...
Image: PD 1. Breast tumors with stem cell mutations in the PI3K/Akt signaling pathway had significantly higher rates of axillary ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
